O	0	9	Influence
O	10	12	of
B-condition	13	20	Obesity
I-condition	21	23	on
I-condition	24	30	Breast
I-condition	31	38	Density
I-condition	39	48	Reduction
O	49	51	by
B-intervention	52	57	Omega
I-intervention	57	58	-
I-intervention	58	59	3
I-intervention	60	65	Fatty
I-intervention	66	71	Acids
O	71	72	:
O	73	81	Evidence
O	82	86	from
O	87	88	a
O	89	99	Randomized
O	100	108	Clinical
O	109	114	Trial
O	114	115	.

O	116	127	Preclinical
O	128	132	data
O	133	141	indicate
O	142	146	that
O	147	152	omega
O	152	153	-
O	153	154	3
O	155	160	fatty
O	161	166	acids
O	167	168	(
O	168	169	n
O	169	170	-
O	170	173	3FA
O	173	174	)
O	175	185	potentiate
O	186	189	the
O	190	205	chemopreventive
O	206	212	effect
O	213	215	of
O	216	219	the
O	220	232	antiestrogen
O	233	234	(
O	234	236	AE
O	236	237	)
O	238	247	tamoxifen
O	248	255	against
O	256	263	mammary
O	264	278	carcinogenesis
O	278	279	.

O	280	283	The
O	284	288	role
O	289	291	of
O	292	293	n
O	293	294	-
O	294	297	3FA
O	298	300	in
O	301	307	breast
O	308	314	cancer
O	315	325	prevention
O	326	328	in
O	329	335	humans
O	336	338	is
O	339	352	controversial
O	352	353	.

O	354	365	Preclinical
O	366	369	and
O	370	383	epidemiologic
O	384	388	data
O	389	396	suggest
O	397	401	that
O	402	403	n
O	403	404	-
O	404	407	3FA
O	408	411	may
O	412	414	be
O	415	429	preferentially
O	430	440	protective
O	441	443	in
O	444	449	obese
O	450	458	subjects
O	458	459	.

O	460	462	To
O	463	471	directly
O	472	476	test
O	477	480	the
O	481	491	protective
O	492	498	effect
O	499	501	of
O	502	503	n
O	503	504	-
O	504	507	3FA
O	508	515	against
O	516	522	breast
O	523	529	cancer
O	529	530	,
O	531	533	we
O	534	543	conducted
O	544	545	a
O	546	547	2
O	547	548	-
O	548	552	year
O	552	553	,
O	554	558	open
O	558	559	-
O	559	564	label
O	565	575	randomized
O	576	584	clinical
O	585	590	trial
O	591	593	in
B-total-participants	594	597	266
B-eligibility	598	605	healthy
I-eligibility	606	620	postmenopausal
I-eligibility	621	626	women
I-eligibility	627	628	(
I-eligibility	628	630	50
I-eligibility	630	631	%
I-eligibility	632	638	normal
I-eligibility	639	645	weight
I-eligibility	645	646	,
I-eligibility	647	649	30
I-eligibility	649	650	%
I-eligibility	651	661	overweight
I-eligibility	661	662	,
I-eligibility	663	665	20
I-eligibility	665	666	%
I-eligibility	667	672	obese
I-eligibility	672	673	)
I-eligibility	674	678	with
I-eligibility	679	683	high
I-eligibility	684	690	breast
I-eligibility	691	698	density
I-eligibility	699	700	(
I-eligibility	700	702	BD
I-eligibility	702	703	;
I-eligibility	704	705	â‰¥
I-eligibility	705	707	25
I-eligibility	707	708	%
I-eligibility	708	709	)
O	710	718	detected
O	719	721	on
O	722	727	their
O	728	735	routine
O	736	745	screening
O	746	756	mammograms
O	756	757	.

O	758	766	Eligible
O	767	772	women
O	773	777	were
O	778	788	randomized
O	789	791	to
O	792	795	one
O	796	798	of
O	799	802	the
O	803	812	following
O	813	817	five
O	818	824	groups
O	825	826	(
O	826	827	i
O	827	828	)
B-control	829	831	no
I-control	832	841	treatment
I-control	841	842	,
I-control	843	850	control
O	850	851	;
O	852	853	(
O	853	855	ii
O	855	856	)
O	857	867	raloxifene
O	868	870	60
O	871	873	mg
O	873	874	;
O	875	876	(
O	876	879	iii
O	879	880	)
O	881	891	raloxifene
O	892	894	30
O	895	897	mg
O	897	898	;
O	899	900	(
O	900	902	iv
O	902	903	)
O	904	905	n
O	905	906	-
O	906	909	3FA
O	910	916	lovaza
O	917	918	4
O	919	920	g
O	920	921	;
O	922	925	and
O	926	927	(
O	927	928	v
O	928	929	)
O	930	936	lovaza
O	937	938	4
O	939	940	g
O	941	945	plus
O	946	956	raloxifene
O	957	959	30
O	960	962	mg
O	962	963	.

O	964	967	The
O	968	969	2
O	969	970	-
O	970	974	year
B-outcome-Measure	975	981	change
I-outcome-Measure	982	984	in
I-outcome-Measure	985	987	BD
O	987	988	,
O	989	990	a
O	991	1000	validated
O	1001	1010	biomarker
O	1011	1013	of
O	1014	1020	breast
O	1021	1027	cancer
O	1028	1032	risk
O	1032	1033	,
O	1034	1037	was
O	1038	1041	the
O	1042	1049	primary
O	1050	1058	endpoint
O	1059	1061	of
O	1062	1065	the
O	1066	1071	study
O	1071	1072	.

O	1073	1075	In
O	1076	1082	subset
O	1083	1091	analysis
O	1091	1092	,
O	1093	1095	we
O	1096	1102	tested
O	1103	1106	the
O	1107	1119	prespecified
O	1120	1130	hypothesis
O	1131	1135	that
O	1136	1140	body
O	1141	1145	mass
O	1146	1151	index
O	1152	1153	(
O	1153	1156	BMI
O	1156	1157	)
O	1158	1168	influences
O	1169	1172	the
O	1173	1185	relationship
O	1186	1193	between
O	1194	1200	plasma
O	1201	1202	n
O	1202	1203	-
O	1203	1206	3FA
O	1207	1209	on
O	1210	1212	BD
O	1212	1213	.

O	1214	1219	While
O	1220	1224	none
O	1225	1227	of
O	1228	1231	the
O	1232	1245	interventions
O	1246	1254	affected
O	1255	1257	BD
O	1258	1260	in
O	1261	1264	the
O	1265	1274	intention
O	1274	1275	-
O	1275	1277	to
O	1277	1278	-
O	1278	1283	treat
O	1284	1292	analysis
O	1292	1293	,
B-outcome	1294	1302	increase
I-outcome	1303	1305	in
I-outcome	1306	1312	plasma
I-outcome	1313	1316	DHA
O	1317	1320	was
O	1321	1331	associated
O	1332	1336	with
O	1337	1338	a
B-outcome	1339	1347	decrease
I-outcome	1348	1350	in
I-outcome	1351	1359	absolute
I-outcome	1360	1366	breast
I-outcome	1367	1374	density
O	1375	1378	but
O	1379	1383	only
O	1384	1386	in
O	1387	1399	participants
O	1400	1404	with
O	1405	1408	BMI
O	1409	1410	>
O	1410	1412	29
O	1412	1413	.

O	1414	1417	Our
O	1418	1425	results
O	1426	1433	suggest
O	1434	1438	that
O	1439	1444	obese
O	1445	1450	women
O	1451	1454	may
O	1455	1469	preferentially
O	1470	1480	experience
O	1481	1487	breast
O	1488	1494	cancer
O	1495	1499	risk
O	1500	1509	reduction
O	1510	1514	from
O	1515	1516	n
O	1516	1517	-
O	1517	1520	3FA
O	1521	1535	administration
O	1535	1536	.
